- Home
- CNF vs TPST Comparison
CNF vs TPST Comparison
Compare CNF & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- TPST
- Stock Information
- Founded
- CNF 1999
- TPST 2011
- Country
- CNF China
- TPST United States
- Employees
- CNF 691
- TPST N/A
- Industry
- CNF Finance: Consumer Services
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- TPST Health Care
- Exchange
- CNF Nasdaq
- TPST Nasdaq
- Market Cap
- CNF 35.7M
- TPST 33.0M
- IPO Year
- CNF 2018
- TPST N/A
- Fundamental
- Price
- CNF $0.66
- TPST $6.91
- Analyst Decision
- CNF
- TPST Hold
- Analyst Count
- CNF 0
- TPST 3
- Target Price
- CNF N/A
- TPST $30.00
- AVG Volume (30 Days)
- CNF 301.2K
- TPST 247.2K
- Earning Date
- CNF 04-30-2025
- TPST 08-07-2025
- Dividend Yield
- CNF N/A
- TPST N/A
- EPS Growth
- CNF N/A
- TPST N/A
- EPS
- CNF 0.08
- TPST N/A
- Revenue
- CNF $85,661,735.00
- TPST N/A
- Revenue This Year
- CNF $252.34
- TPST N/A
- Revenue Next Year
- CNF N/A
- TPST N/A
- P/E Ratio
- CNF $8.31
- TPST N/A
- Revenue Growth
- CNF N/A
- TPST N/A
- 52 Week Low
- CNF $0.37
- TPST $5.35
- 52 Week High
- CNF $2.84
- TPST $30.03
- Technical
- Relative Strength Index (RSI)
- CNF 61.10
- TPST 45.96
- Support Level
- CNF $0.42
- TPST $6.75
- Resistance Level
- CNF $0.66
- TPST $7.18
- Average True Range (ATR)
- CNF 0.08
- TPST 0.37
- MACD
- CNF 0.02
- TPST -0.04
- Stochastic Oscillator
- CNF 64.71
- TPST 16.71
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.